Erratum (DOI:10.1016/j.jash.2010.02.005);Combination therapy in hypertension

Journal of the American Society of Hypertension

Volumn 4, Issue 1, 2010, Pages 42-50

  Gradman, Alan H ^a   Basile, Jan N ^b   Carter, Barry L ^c   Bakris, George L ^d  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

angiotensin converting enzyme inhibitor; angiotensin receptor blocker; beta blockers diuretic; calcium channel blocker; combination therapy; drug therapy; Hypertension

Indexed keywords

ALISKIREN; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METHYLDOPA; METOPROLOL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRIAMTERENE; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GLUCOSE INTOLERANCE; HEART BLOCK; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 77749332022     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2010.04.001     Document Type: Erratum

References (65)

1. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. National High Blood Pressure Education Program Coordinating Committee: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1105-1187
3. Williams B., Poulter N.R., Brown M.J., et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHSIV. J Hum Hypertens 18 (2004) 139-185
4. Mancia G., Laurent S., Agabati-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27 (2009) 2121-2158
5. Rosendorff C., et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and epidemiology and Prevention. Circulation 115 (2007) 2761-2788
6. Coleman T.G., and Hall J.E. Systemic hemodynamics and regional blood flow regulation. In: Izzo Jr. J.L., Black H.R., and Sica D.A. (Eds). Hypertension primer. 4th ed (2008), Lippincott, Williams and Wilkins, Philadelphia PA
7. Law M.R., Wald N.J., Morris J.K., and Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427-1435
8. Neaton J.D., Grimm Jr. R.H., Prineas R.J., et al. Treatment of Mild Hypertension Study. JAMA 270 (1993) 713-724
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
10. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
11. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
12. Dickerson J.E., Hingorani A.D., et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353 (1999) 2008-2013
13. Mourad J., Waeber B., and Zinnad F. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 22 (2004) 2379-2386
14. Kotsis V., Stabouli S., Bouldin M., et al. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension 45 (2005) 602-607
15. Izzo R., deSimone G., Chinali M., et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 32 (2009) 845-850
16. Wald D.S., Law M., Morris J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 122 (2009) 290-300
17. Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62 (2002) 243-262
18. Gradman A.H., and Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 4 (2002) 343-349
19. Fung V., Huang J., Brand R., Newhouse J.P., and Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 29 (2007) 972-984
20. Dunbar-Jacob. 2009, NHLBI Implementation Conference.
21. Bangalore S., Kamalakkannan G., Parkar S., et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120 (2007) 713-719
22. Chrysant S.G. Antihypertensive effectiveness of low-dose lisinopril hydrochlorothiazide combination. Arch Intern Med 154 (1994) 737-743
23. Chrysant S.G., Fagan T., Glazer R., and Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 5 (1996) 17-24
24. Pool J., Cushman W.C., Saini R.K., et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens 10 (1997) 117-123
25. Gradman A.H., and Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 51 (2008) 519-528
26. Mackay J.H., Arcuri K.E., Goldberg A.I., et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 156 (1996) 278-285
27. Ambrosioni E., Borghi C., and Costa F.V. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol 23 Suppl. 1 (1987) 43S-50S
28. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
29. Frishman W.H., Ram C.V.S., McMahon F.G., et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 35 (1995) 1060-1066
30. Philipp T., Smith T.R., Glazer R., et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29 (2007) 563-580
31. Chrysant S.G., Melino M., Karki S., et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, controlled, 8-week factorial efficacy and safety study. Clin Ther 30 (2008) 587-604
32. Gradman A.H., Cutler N.R., Davis P.J., et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 79 (1997) 431-435
33. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., et al., for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
34. Weber M.A., Bakris G.L., Dahlöf B., et al., for the ACCOMPLISH Investigators. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 16 (2007) 13-19
35. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
36. Oparil S., Yarows S.A., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet 370 (2007) 221-229
37. Salvetti A., Magagna A., Innocenti P., et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol 17 (1991) 332-335
38. Weir M.R., Weber M.A., Punzi H.A., et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 6 (1992) 133-138
39. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
40. Carlberg B., Samuelsson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
41. Lindholm L.H., Carlberg B., and Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
42. Bradley H.A., Wiysonge C.S., Volmink J.A., et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24 (2006) 2131-2141
43. Saunders E., Weir M.R., Kong B.W., et al. A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150 (1990) 1707-1713
44. Frishman W.H., Bryzinski B.S., Coulson L.R., et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 154 (1994) 1461-1468
45. Bateman D.N., Dean C.R., Mucklow J.C., et al. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 7 (1979) 357-363
46. Lacourcière Y., and Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 8 (1994) 283-288
47. Gradman A.H. Drug combinations. In: Izzo Jr. J.L., Black H.R., and Sica D.A. (Eds). Hypertension primer. 4th ed (2008), Lippincott, Williams, and Wilkins, Philadelphia PA
48. Siscovick D.S., Raghunathan T.E., Psaty B.M., et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330 (1994) 1852-1857
49. Calhoun D.A. Resistant or difficult-to-treat hypertension. J Clin Hypertens 8 (2006) 181-186
50. Myers M.G. Hydrochlorothiazide with or without amiloride for hypertension in the elderly: a dose-titration study. Arch Intern Med 147 (1987) 1026-1030
51. Guerrero P., Fuchs F.D., and Moreria L.M. Blood pressure lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens 30 (2008) 553-564
52. Khosla N., Kalaitzidis R., and Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30 (2009) 418-424
53. Dahlöf B., Degl' Innocenti A., Elmfeldt D., et al. Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens 18 (2005) 1313-1319
54. Frishman W.H., Hainer J.W., and Sugg J. M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release: results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens 19 (2006) 388-395
55. Wing L.M.H., Chalmers J.P., West M.J., et al. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens 10 (1988) 119-133
56. Mehta J.L., and Lopez L.M. Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol. Arch Intern Med 147 (1987) 389-390
57. Weber M.A., Julius S., Kjeldsen S.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 (2004) 2049-2051
58. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816
59. Mancia G., Messerli F., Bakris G., Zhou Q., Champion A., and Pepine C.J. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 50 (2007) 299-305
60. Weir M., Levy D., Crikelair N., Rocha R., Meng X., and Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 20 (2007) 807-815
61. Jamerson K., Bakris G.L., Dahlöf B., et al., for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 16 (2007) 80-86
62. Feldman R.D., Zou G.Y., Vandervoort M.K., Wong C.J., Nelson S.A.E., and Feagan B.G. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53 (2009) 646-653
63. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 9 9 Suppl (2000) 2-6
64. Egan B.M. Fixed-dose combinations and hypertension control in community-based practices: application of the "keep-it-simple" principle. Hypertension 53 (2009) 598-599
65. Carter B.L., Bergus G.R., and Dawson J.D. Evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens 10 (2008) 260-271